Cargando…
既往吉非替尼治疗获益的晚期NSCLC患者再次使用EGFR-TKI的选择：原药还是换药？
BACKGROUND AND OBJECTIVE: For advanced non-small cell lung cancer (NSCLC) patients who benefited from prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy, the choice of a second TKI therapy has gradually become a new strategy for the treatment. Some investigators reco...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000651/ https://www.ncbi.nlm.nih.gov/pubmed/23866664 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.07.03 |